SCHEMBL2032280

SCHEMBL2032280

Cc1cc(C#N)ccc1-c1c(-c2ccc(N)cc2)csc1C=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 3/20 0.37
EIF4E P06730 1/20 0.36
APP P05067 1/20 0.35
PDE4A P27815 1/20 0.33
HRH2 P25021 1/20 0.32
HRH1 P35367 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
STS P08842 1/20 0.32
PRKCZ Q05513 1/20 0.32
HSP90AB1 P08238 1/20 0.32
GAA P10253 1/20 0.32
GRM2 Q14416 1/20 0.31
SCN9A Q15858 1/20 0.31
S1PR1 P21453 1/20 0.31
NSD2 O96028 1/20 0.31
KDM1A O60341 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2034990 0.86 CYP1A1 (0.41) EIF4EHRH2HRH1STS
SCHEMBL12541140 0.85 EIF4E (0.38) EGLN2EIF4EAPPHRH2HRH1
SCHEMBL12541138 0.85 EIF4E (0.38) EGLN2EIF4EAPPHRH2HRH1
SCHEMBL2033738 0.81 PRKCZ (0.41) EIF4EHRH2HRH1PRKCZHSP90AB1
SCHEMBL2033741 0.81 PRKCZ (0.41) EIF4EHRH2HRH1PRKCZHSP90AB1
SCHEMBL2035965 0.80 PDE4A (0.36) EGLN2EIF4EPDE4ASCN9AS1PR1
SCHEMBL2052330 0.80 ALDH1A1 (0.42) EGLN2EIF4EPDE4APDE3BPDE3A
SCHEMBL2033179 0.74 PRKCZ (0.43) EIF4EHRH2HRH1PRKCZHSP90AB1
SCHEMBL2034932 0.73 MAPK14 (0.38) EIF4EHRH2HRH1
SCHEMBL6514538 0.71 HRH2 (0.41) EGLN2EIF4EHRH2HRH1PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859611-B2 Thiophene inhibitors of S-nitrosoglutathione reductase N30 PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
EP-2512247-B1 NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE N30 PHARMACEUTICALS INC (US) 2014-06-04 EP disclosed
US-20140057957-A1 Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase N30 PHARMACEUTICALS, INC. (US) 2014-02-27 US disclosed
US-8586624-B2 Thiophene inhibitors of S-nitrosoglutathione reductase N30 PHARMACEUTICALS, INC. (US) 2013-11-19 US disclosed
EP-2512247-A1 NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE N30 Pharmaceuticals, LLC (US) 2012-10-24 EP disclosed
US-20120245210-A1 Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase N30 PHARMACEUTICALS, LLC (US) 2012-09-27 US disclosed
WO-2011075478-A1 NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE N30 PHARMACEUTICALS, LLC (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057957-A1 Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase GSR, GRHPR, POR EGLN2 2496/4885EIF4E 4655/4885APP 4176/4885
US-20120245210-A1 Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase GSR, GRHPR, POR EGLN2 2496/4885EIF4E 4655/4885APP 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.